☆ 4.7 Letter

Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency

ANNALS OF THE RHEUMATIC DISEASES (2019)

期刊

ANNALS OF THE RHEUMATIC DISEASES

卷 78, 期 3, 页码 431-+

出版社

BMJ PUBLISHING GROUP

DOI: 10.1136/annrheumdis-2018-214037

关键词

-

类别

Rheumatology

资金

Institut National de la Sante et de la Recherche Medicale [000427993]
European Research Council [GA 309449]
National Research Agency (France) under the 'Investments for the Future' programme [ANR-10-IAHU-01]
ANR [CE17001002]

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Dermatology

Lupus erythematosus

Claudia Guenther, Joerg Wenzel

Summary: Cutaneous lupus erythematosus can present with or without systemic involvement, resulting in a wide range of clinical manifestations. The disease is characterized by a loss of tolerance to endogenous antigens and chronic activation of the immune system. Although our understanding of the disease pathogenesis has improved, treatment options remain limited. Biologics targeting BLyS or the type I interferon receptor have shown promising results in patients with cutaneous involvement and systemic lupus erythematosus. However, conducting clinical trials is challenging due to the variability of symptoms. Nonetheless, focusing on cutaneous manifestations as primary endpoints may lead to better treatment options for SLE in the future.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2023)

添加到收藏夹

Article Immunology

A Novel Type I Interferon Primed Dendritic Cell Subpopulation in TREX1 Mutant Chilblain Lupus Patients

Anne Eugster, Denise Mueller, Anne Gompf, Susanne Reinhardt, Annett Lindner, Michelle Ashton, Nick Zimmermann, Stefan Beissert, Ezio Bonifacio, Claudia Guenther

Summary: This study analyzed the composition of dendritic cell subsets in patients with TREX1 deficiency and identified a novel myeloid dendritic cell subpopulation that is highly enriched in these patients and associated with upregulation of interferon pathway genes.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Hematology

Efficacy of JAK1/2 inhibition in murine immune bone marrow failure

Emma M. Groarke, Xingmin Feng, Nidhi Aggarwal, Ash Lee Manley, Zhijie Wu, Shouguo Gao, Bhavisha A. Patel, Jichun Chen, Neal S. Young

Summary: Immune aplastic anemia (AA) is a severe blood disease characterized by T-lymphocyte-mediated stem cell destruction. The Janus kinase (JAK) 1/2 inhibitor ruxolitinib (RUX) has shown potential therapeutic benefit in murine immune AA models. RUX attenuates bone marrow hypoplasia, ameliorates pancytopenia, and prevents mortality by suppressing T cell activation and inhibiting cytokine production.

BLOOD (2023)

添加到收藏夹

Article Oncology

Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

Raajit K. Rampal, Maria Pinzon-Ortiz, Amritha Varshini Hanasoge Somasundara, Benjamin Durham, Richard Koche, Barbara Spitzer, Shoron Mowla, Aishwarya Krishnan, Bing Li, Wenbin An, Andriy Derkach, Sean Devlin, Xianhui Rong, Tyler Longmire, Shira Esther Eisman, Keith Cordner, Justin T. Whitfield, Gary Vanasse, Zhu A. Cao, Ross L. Levine

Summary: Combining the JAK1/2 inhibitor ruxolitinib with a CDK4/6 inhibitor (LEE011) and a PIM kinase inhibitor (PIM447) has shown to be effective in improving therapeutic responses in patients with myeloproliferative neoplasms (MPN), leading to reductions in spleen and liver size, improvement in bone marrow fibrosis, increased overall survival, and elimination of disease-initiating capacity in murine models of MPN, as well as reduced colony formation capacity in primary MPN patient samples.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Clinical Neurology

Case report: JAK inhibition as promising treatment option of fatal RVCLS due to TREX1 mutation (pVAL235Glyfs*6)

Friederike Ufer, Susanne M. Ziegler, Marcus Altfeld, Manuel A. Friese

Summary: This study reported on the treatment of a patient with RVCLS using anti-retroviral drugs and the JAK inhibitor ruxolitinib. The treatment was well-tolerated and clinically stabilized the disease activity. JAK inhibition may be a safe and effective treatment option for RVCLS.

FRONTIERS IN NEUROLOGY (2023)

添加到收藏夹

Article Urology & Nephrology

A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Faslpr mice with proliferative lupus nephritis predicts low effect size

Yutian Lei, Bettina Sehnert, Reinhard E. Voll, Conxita Jacobs-Cacha, Maria Jose Soler, Maria D. Sanchez-Nino, Alberto Ortiz, Roman D. Buelow, Peter Boor, Hans-Joachim Anders

Summary: The study conducted a multicenter preclinical randomized controlled trial in the kidney domain to evaluate the effect of Jak1/2 inhibition in lupus nephritis. The results showed that while multicenter trials can reduce single-center bias, they may also increase data heterogeneity and reduce effect size. Phenotype differences among mice bred at different sites were noted, mirroring patient phenotype diversity seen in lupus trials.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Immunology

Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata

Zhenpeng Dai, Tanya Sezin, Yuqian Chang, Eunice Y. Lee, Eddy Hsi Chun Wang, Angela M. Christiano

Summary: This study found that the JAK inhibitor Ifidancitinib can effectively promote hair regrowth in AA mice. Ifidancitinib can alleviate AA-associated inflammation and reduce the number of T cells associated with the pathogenesis of AA. The study also found that the expression of co-inhibitory receptor PD-1 on effector/memory CD8(+) T cells increased, while IFN-gamma production decreased in Ifidancitinib-treated mice. The study suggests that selective induction of T cell exhaustion using a JAK inhibitor may be one of the mechanisms underlying the success of this treatment strategy in reversing autoimmune diseases such as AA.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Allergy

JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis

Anna Sophie Klaeschen, Tim Joachim Nuemm, Nadine Herrmann, Nicole Leib, Laura Maintz, Takashi Sakai, Joerg Wenzel, Thomas Bieber

Summary: JAK inhibitors show significant therapeutic effects in atopic dermatitis by affecting the differentiation and function of inflammatory dendritic epidermal cells. Specifically, JAK1/2 inhibitors can prevent IDEC differentiation and influence cell redifferentiation.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease

Tatsuma Ban, Masako Kikuchi, Go R. Sato, Akio Manabe, Noriko Tagata, Kayo Harita, Akira Nishiyama, Kenichi Nishimura, Ryusuke Yoshimi, Yohei Kirino, Hideyuki Yanai, Yoshiko Matsumoto, Shuichi Suzuki, Hiroe Hihara, Masashi Ito, Kappei Tsukahara, Kentaro Yoshimatsu, Tadashi Yamamoto, Tadatsugu Taniguchi, Hideaki Nakajima, Shuichi Ito, Tomohiko Tamura

Summary: IRF5 is a potential therapeutic target for systemic lupus erythematosus (SLE). Studies show that inhibition of IRF5 after disease onset can suppress disease progression and maintain remission effectively. Inhibiting IRF5 may overcome the limitations of current SLE therapies.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Immunology

Treatment with a JAK1/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression

Tihong Shao, Patrick S. C. Leung, Weici Zhang, Koichi Tsuneyama, William M. Ridgway, Howard A. Young, Zongwen Shuai, Aftab A. Ansari, M. Eric Gershwin

Summary: By inhibiting the JAK/STAT signaling pathway, the development and progression of autoimmune cholangitis can be effectively blocked. This study found that ruxolitinib treatment can reduce inflammation, lower autoantibody levels, and alter macrophage polarization, which holds important immunological and clinical significance for cholangitis.

CELLULAR & MOLECULAR IMMUNOLOGY (2022)

添加到收藏夹

Article Immunology

A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages

Jiawen Zhang, Peiyu Jiang, Lei Sheng, Yunyi Liu, Yixuan Liu, Min Li, Meng Tao, Liang Hu, Xiaoyan Wang, Yanjing Yang, Yang Xu, Wentao Liu

Summary: The study indicates that carvedilol is effective in treating rosacea by inhibiting TLR2 expression, alleviating inflammation in mouse models, and improving clinical manifestations in patients with rosacea.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Nutrition & Dietetics

Treatment of Vitamin D Deficiency with Calcifediol: Efficacy and Safety Profile and Predictability of Efficacy

Jose-Luis Perez-Castrillon, Ricardo Usategui-Martin, Pawel Pludowski

Summary: Calcifediol is the prohormone of the vitamin D endocrine system, used to prevent and treat vitamin D deficiency. It is more efficient and safe than cholecalciferol, with a rapid onset of action and greater potency. The increase in 25-OH vitamin D depends on the dose and frequency of calcifediol administration, while cholecalciferol administration is influenced by additional factors such as obesity and malabsorption.

NUTRIENTS (2022)

添加到收藏夹

Review Dermatology

Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy

Benjamin F. Chong, Victoria Werth

Summary: Important developments in defining cutaneous lupus erythematosus and dermatomyositis have had a profound impact on quality of life, facilitating current and future scientific and therapeutic advancements.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth

Lilly Velentza, Malin Wickstrom, Per Kogner, Claes Ohlsson, Farasat Zaman, Lars Savendahl

Summary: Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax, a BCL-2 inhibitor, has shown efficacy in hematological malignancies in adults and is being investigated in pediatric cancer clinical trials. However, our experimental data suggest that Venetoclax directly targets growth plate chondrocytes, suppressing bone growth. Therefore, careful monitoring of longitudinal bone growth is encouraged when treating growing children with Venetoclax.

SCIENTIFIC REPORTS (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Inhibition of JAK1/STAT3 pathway by 2-methoxyestradiol ameliorates psoriatic features in vitro and in an imiquimod-induced psoriasis-like mouse model

Jiaxuan Tang, Chaofan Liu, Shiying Liu, Xing Zhou, Jinghao Lu, Ming Li, Lubing Zhu

Summary: 2-Methoxyestradiol (2-ME) has shown significant inhibition on proliferation, angiogenesis, and inflammation, making it a promising therapeutic agent for psoriasis.

EUROPEAN JOURNAL OF PHARMACOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi-Goutieres syndrome

Velda X. Han, Shekeeb S. Mohammad, Hannah F. Jones, Sushil Bandodkar, Yanick J. Crow, Russell C. Dale

Summary: In the treatment of Aicardi-Goutières syndrome (AGS), Janus kinase (JAK) 1 inhibition shows a precision medicine approach targeting type I interferon-mediated cell signaling. Elevated cerebrospinal fluid (CSF) neopterin levels in AGS patients decreased significantly in response to JAK inhibitors, indicating a potential role for CSF neopterin as a biomarker of treatment response.

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2022)

添加到收藏夹

Article Genetics & Heredity

Systemic inflammatory syndrome in children with FARSA deficiency

Fabienne Charbit-Henrion, Roman Goguyer-Deschaumes, Keren Borensztajn, Marc Mirande, Jeremy Berthelet, Fernando Rodrigues-Lima, Anis Khiat, Marie-Louise Fremond, Brigitte Bader-Meunier, Marco M. Rodari, Luis Seabra, Gillian Rice, Marie Legendre, David Drummond, Laureline Berteloot, Charles-Joris Roux, Nathalie Boddaert, Philippe Drabent, Thierry Jo Molina, Florence Lacaille, Manoelle Kossorotoff, Nadine Cerf-Bensussan, Marianna Parlato, Alice Hadchouel

Summary: Variants in aminoacyl-tRNA synthetases (ARSs) genes are associated with a wide range of human inherited diseases, with defective PheRS leading to symptoms like brain abnormalities. Furthermore, FARSA deficiency can cause inflammation and autoimmunity, with JAK inhibition showing improvement in lung disease.

CLINICAL GENETICS (2022)

添加到收藏夹

Review Medicine, General & Internal

point Quand penser a une interf?ronopathie de type I chez l?adulte ? When to consider type I interferonopathy in adulthood?

C. David, M. -L. Fremond

Summary: Type I interferonopathies are a group of heterogeneous genetic diseases characterized by constitutive activation of the type I interferon pathway. Patients typically present with central nervous system involvement, skin vasculitis, joint abnormalities, and hematologic abnormalities. Targeted therapies inhibiting type I interferon show promise in improving symptoms for these patients.

REVUE DE MEDECINE INTERNE (2022)

添加到收藏夹

Article Immunology

DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling

Maud Tusseau, Ema Lovsin, Charlotte Samaille, Remi Pescarmona, Anne-Laure Mathieu, Maria-Cristina Maggio, Velma Selmanovic, Marusa Debeljak, Angelique Dachy, Gregor Novljan, Alexandre Janin, Louis Januel, Jean-Baptiste Gibier, Emilie Chopin, Isabelle Rouvet, David Goncalves, Nicole Fabien, Gillian Rice, Gaetan Lesca, Audrey Labalme, Paola Romagnani, Thierry Walzer, Sebastien Viel, Magali Perret, Yanick J. Crow, Tadej Avcin, Rolando Cimaz, Alexandre Belot

Summary: The interferon signaling in DNASE1L3 deficient patients is transient, unlike the anomalies observed in other diseases. DNASE1L3 deficiencies are associated with a broad phenotype including lupus nephritis and hypocomplementemic urticarial vasculitis.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Review Clinical Neurology

Delineating the epilepsy phenotype of NRROS-related microgliopathy: A case report and literature review

Priyanka Madaan, Yashovardhan Kaushal, Priyanka Srivastava, Yanick J. Crow, John H. Livingston, Chirag Ahuja, Naveen Sankhyan

Summary: Pathogenic variants in the NRROS gene are associated with infantile spasms syndrome and progressive neurodegeneration. Among the 11 identified children, 7 had normal early development. All children had a history of drug-resistant epilepsy, with 3 experiencing epileptic spasms. The median age at seizure onset and developmental regression was 12 months and the median age at death was 36 months. Eight of the children had intracranial calcifications and neuroimaging showed progressive cerebral atrophy and white matter loss.

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2022)

添加到收藏夹

Article Immunology

Juvenile Neuropsychiatric Systemic Lupus Erythematosus: Identification of Novel Central Neuroinflammation Biomarkers

Mathilde Labouret, Stefania Costi, Vincent Bondet, Vincent Trebossen, Enora Le Roux, Alexandra Ntorkou, Sophie Bartoli, Stephane Auvin, Brigitte Bader-Meunier, Veronique Baudouin, Olivier Corseri, Glory Dingulu, Camille Ducrocq, Cecile Dumaine, Monique Elmaleh, Nicole Fabien, Albert Faye, Isabelle Hau, Veronique Hentgen, Theresa Kwon, Ulrich Meinzer, Naim Ouldali, Cyrielle Parmentier, Marie Pouletty, Florence Renaldo, Isabelle Savioz, Flore Rozenberg, Marie-Louise Fremond, Alice Lepelley, Gillian I. Rice, Luis Seabra, Jean-Francois Benoist, Darragh Duffy, Yanick J. Crow, Pierre Ellul, Isabelle Melki

Summary: This study aimed to identify central nervous system (CNS) disease biomarkers of juvenile neuropsychiatric SLE (j-NPSLE). The results showed that cerebrospinal fluid (CSF) levels of neopterin and interferon-alpha (IFN-alpha) protein were significantly higher in active j-NPSLE cases with CNS involvement compared to j-SLE alone. These biomarkers could potentially be useful in the diagnosis and monitoring of j-NPSLE activity.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Letter Immunology

Clinical Non-penetrance Associated with Biallelic Mutations in the RNase H2 Complex

Yanick J. Crow

JOURNAL OF CLINICAL IMMUNOLOGY (2023)

添加到收藏夹

Letter Immunology

STING-Associated Vasculopathy with Onset in infancy (SAVI) Presenting as Massive Intra Alveolar Hemorrhage

Clara Ladoux, Marlene Pasquet, Yanick J. J. Crow, Marie Louise Fremond, Lea Roditis

JOURNAL OF CLINICAL IMMUNOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Early systemic inflammation induces neurodevelopmental disorders: results from ARTEMIS, a French multicenter study of juvenile rheumatisms and systemic autoimmune and auto-inflammatory disorders and meta-analysis

Pierre Ellul, Isabelle Melki, Stephanie Antoun, Laura Lavialle, Eric Acquaviva, Florence A. Aeschlimann, Brigitte Bader-Meunier, Alexandre Belot, Glory Dingulu, Cecile Dumaine, Albert Faye, Marie-Louise Fremond, Ulrich Meinzer, Hugo Peyre, Pierre Quartier, Michelle Rosenzwajg, Isabelle Savioz, Caroline Vinit, Nicolas Tchitchek, David Klatzmann, Richard Delorme

Summary: Prenatal immune-mediated events are known risk factors for neurodevelopmental disorders in the offspring. This study establishes a cohort of juvenile rheumatisms and systemic autoimmune and auto-inflammatory disorders (jRSAID) to assess their neurodevelopment and conducts a systematic review and meta-analysis. The results suggest a positive association between jRSAID and NDD, with age at onset and delay in introduction of disease-modifying therapy playing pivotal roles in the risk of developing NDD.

MOLECULAR PSYCHIATRY (2023)

添加到收藏夹

Letter Rheumatology

Osteonecrosis in patients with juvenile dermatomyositis: is it associated with anti-MDA5 autoantibody?

Brigitte Bader-Meunier, Sylvain Breton, Darragh Duffy, Cyril Gitiaux, Pierre Quartier, Irene Lemelle, Alain Meyer, Anne Welfringer-Morin, Marie-Louise Fremond, Jean-Luc Charuel, Mathieu P. Rodero, Isabelle Melki

RHEUMATOLOGY (2023)

添加到收藏夹

Article Rheumatology

2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice

Javier Rodriguez-Carrio, Agata Burska, Philip G. Conaghan, Willem A. Dik, Robert Biesen, Maija-Leena Eloranta, Giulio Cavalli, Marianne Visser, Dimitrios T. Boumpas, George Bertsias, Marie Wahren-Herlenius, Jan Rehwinkel, Marie-Louise Fremond, Mary K. Crow, Lars Ronnblom, Marjan A. Versnel, Edward M. Vital

Summary: This study developed evidence-based points to consider for the measurement and reporting of IFN-I assays in clinical research. The study provides recommendations on terminology, assay characteristics, and reporting practices, as well as explores the clinical applications of IFN-I assays in diagnosis and outcome assessments.

ANNALS OF THE RHEUMATIC DISEASES (2023)

添加到收藏夹

Article Immunology

Lung Transplantation under a Janus Kinase Inhibitor in Three Patients with SAVI Syndrome

Kenza Rhzioual Berrada, Alexandre Belot, Benedicte Neven, Camille Ohlmann, Francois Tronc, Gillian Rice, Guillaume Thouvenin, Jean-Christophe Dubus, Julie Mazenq, Marie-Louise Fremond, Nathalie Stremler, Severine Soummer-Feuillet, Vincent Cottin, Philippe Reix

Summary: STING-associated vasculopathy with onset in infancy (SAVI) is a rare autoinflammatory disease characterized by fever attacks and skin and respiratory manifestations. Respiratory involvement occurs in 80% of cases and may require lung transplantation. Three patients with SAVI who underwent lung transplantation have been reported, but their diagnosis was made after transplantation, preventing targeted therapy.

JOURNAL OF CLINICAL IMMUNOLOGY (2023)

添加到收藏夹

Review Medicine, General & Internal

JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases

Isabelle Melki, Marie-Louise Fremond

Summary: Juvenile idiopathic arthritis (JIA) is a diverse group of diseases with different underlying physiopathology. Treatment options are limited for some patients due to severe disease, drug adverse events, drug allergy, or association with severe comorbidities. Janus Kinase (JAK) inhibitors show promise in providing an alternative treatment for these cases and may also be beneficial for patients with Mendelian disorders resembling JIA. However, more research is needed to evaluate their long-term safety and identify subsets of JIA patients who will benefit from these treatments.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Meeting Abstract Dermatology

HY209, a GPCR19 agonist, ameliorates atopic dermatitis in mice

F. Assan, A. Izmiryan, M. Fremond, H. Bachelez

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

添加到收藏夹

Review Immunology

The type I interferonopathies: 10 years on

Yanick J. Crow, Daniel B. Stetson

Summary: The term 'type I interferonopathy' was coined 10 years ago to describe rare genetic diseases caused by aberrant upregulation of type I interferon signaling. Viral nucleic acid detection is crucial for effective immune response, but failure in self versus non-self discrimination can lead to Mendelian inborn errors of immunity characterized by upregulation of type I interferon signaling.

NATURE REVIEWS IMMUNOLOGY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.